Volume 24, Number 9—September 2018
Maripa Virus RNA Load and Antibody Response in Hantavirus Pulmonary Syndrome, French Guiana
Highlight and copy the desired format.
|EID||Matheus S, Kallel H, Roux A, Bremand L, Labeau B, Moua D, et al. Maripa Virus RNA Load and Antibody Response in Hantavirus Pulmonary Syndrome, French Guiana. Emerg Infect Dis. 2018;24(9):1734-1736. https://dx.doi.org/10.3201/eid2409.180223|
|AMA||Matheus S, Kallel H, Roux A, et al. Maripa Virus RNA Load and Antibody Response in Hantavirus Pulmonary Syndrome, French Guiana. Emerging Infectious Diseases. 2018;24(9):1734-1736. doi:10.3201/eid2409.180223.|
|APA||Matheus, S., Kallel, H., Roux, A., Bremand, L., Labeau, B., Moua, D....Lavergne, A. (2018). Maripa Virus RNA Load and Antibody Response in Hantavirus Pulmonary Syndrome, French Guiana. Emerging Infectious Diseases, 24(9), 1734-1736. https://dx.doi.org/10.3201/eid2409.180223.|
We report viral RNA loads and antibody responses in 6 severe human cases of Maripa virus infection (2 favorable outcomes) and monitored both measures during the 6-week course of disease in 1 nonfatal case. Further research is needed to determine prevalence of this virus and its effect on other hantaviruses.
Hantaviruses are members of the genus Orthohantavirus (family Hantaviridae) and are carried by various rodent species, depending on the strain. Humans can be infected by inhalation of aerosolized viruses excreted in the urine or feces of infected rodents. New World hantaviruses in the Americas cause hantavirus pulmonary syndrome (HPS) in humans, characterized by fever, headache, cough, myalgia, and nausea, evolving rapidly to pulmonary edema (1,2). This respiratory insufficiency is associated with death in 26%–39% of cases, depending on the New World hantavirus species (3,4).
Following the identification of Sin Nombre virus (SNV) as the etiologic agent of HPS in the United States in 1993, many other hantaviruses have been identified in the Americas (3–6). In French Guiana, a laboratory-confirmed case of hantavirus infection was reported in a hospitalized patient in 2008; the complete sequence analysis showed that this was a novel hantavirus closely related to the Rio Mamore species called Maripa virus (7,8).
We describe antibody responses to Maripa hantavirus infection and viral RNA loads in the 6 laboratory-confirmed human cases in French Guiana, measured at admission to the hospital. We also report how these 2 markers evolved during the course of the disease in the most recent hospitalized case-patient, who had a favorable clinical outcome.
Since the time hantavirus diagnostic tools were set up at French Guiana’s Institut Pasteur in 2008, a total of 6 severe human cases of infection by native hantavirus have been reported. All the patients were male; the mean age was 54.6 years (range 38–71 years). The mean time from onset of the disease until admission to the hospital was 4.6 days (range 2–7 days). The clinical outcome was favorable for 2 of the patients; 4 died (Table 1). The clinical and biologic parameters of the first 5 confirmed hantavirus cases were reported previously (9). The sixth patient was a 47-year-old man who complained of fever, cough, myalgia, and sweating that had been developing over 6 days. He was admitted to the Andrée Rosemon General Hospital in Cayenne, French Guiana, on August 31, 2017. He experienced respiratory failure, requiring rapid transfer to the intensive care unit for intubation and mechanical ventilation. Thoracic radiography revealed bilateral diffuse alveolar pulmonary infiltrates. The patient remained under mechanical ventilation for 18 days and was discharged from the hospital after 23 days with complete clinical recovery. The clinical symptoms of the patient, and his outdoor activities making the contact with rodents possible, led to suspicion of acute hantavirus infection, which was confirmed by molecular and serologic tests. The complete RNA coding sequence of the S RNA segment (GenBank accession no. MG785209) was also generated and compared with those of the other 5 previous hantavirus cases, showing that it corresponded to a Maripa virus infection (9).
We tested serum samples from the 6 HPS case-patients that were collected on admission at the intensive care unit and the other 7 sequential serum samples provided from case-patient 6 (6 samples during the hospitalization and 1 after discharge). We performed serologic IgM and IgG tests and assayed them for viral RNA quantification (Tables 1,2). We obtained informed consent from the patients, their representatives, or both at admission and before discharge.
We assayed all serum samples by IgM capture and IgG ELISA using the protocol described by Ksiazek et al. (10). We tested samples against SNV antigen and control antigen using 4-fold dilutions, from 1:100 to 1:6,400. Because of antibody cross-reactivities, positive ELISA findings with SNV antigens indicated infections with New World hantaviruses. The positive criteria were similar to those described by MacNeil et al. (11).
The serologic investigations showed that all samples collected at admission had detectable amounts of hantavirus IgM: minimum IgM titers >400 for patients 1, 2, 4, 5, and 6 and a maximum titer of >16,00 for patient 3 (Table 1). These data were similar to those reported in previous work (11,12). Only patient 5, who died 24 hours after admission, had serum samples positive for hantavirus IgG (titer >6,400). Although the time from the onset of disease and sample collection at admission was different for each of the 6 patients, this single positive hantavirus IgG case may be explained in part by the longer viral incubation period, resulting in the induction of IgG before the appearance of symptoms. A previous study reported that the presence of hantavirus IgG during the first week of infection might be a predictor of survival, but we found no evidence supporting this view (11).
To determine the viral RNA load in each serum sample, we performed real-time PCR. Each reaction was performed in duplicate. For absolute quantification, we calculated the exact number of copies of the gene of interest using a standard curve established with plasmid DNA at dilutions from 5 to 5 × 107 copies/mL. The viral RNA loads in the samples collected on admission were 5.8–6.6 log10 copies/mL (mean 6.2 ± 0.3 log10 copies/mL) (Table 1). These values were similar to those observed in patients infected by other hantaviruses, including patients with mild or moderate symptoms (13–15). We also observed that the viral RNA load in the 4 fatal cases was 6.2 log10 copies/mL, whereas in the 2 nonfatal cases it was 6.1 log10 copies/mL. A correlation between hantavirus RNA loads in the serum during the acute phase of disease and the clinical outcome has been hypothesized (14,15); however, although our study includes only a small number of cases and only severe cases, it provides no evidence supporting this possibility. Presumably, the fatal or nonfatal outcome depends not only on the hantavirus viral load but also on other pathogenic or host factors.
The progression of these antibody responses and viral RNA loads was also followed during the course of disease for patient 6, from admission to the hospital (day 7) until day 46 after the onset of disease (Table 2). IgM titers were high at admission but decreased to become undetectable by day 46. Conversely, seroconversion (IgM to IgG) was observed between day 7 and day 12; these hantavirus IgG titers then increased to 4.4 by day 46. Likewise, viral RNA load evaluated in these 7 sequential serum samples showed a high value at admission (6.4 log10 copies/mL), declining by 7 days later to 4.7 log10 copies/mL (Table 2). Viral load then remained around 4 log10 copies/mL in samples collected on days 20, 25, and 30 and was undetectable on day 46.
Although limited in sample size, this study found similar results for viral load and immune response in the first 6 cases of Maripa virus infection reported in French Guiana after laboratory-based surveillance began in 2008. Further work is needed to determine the overall prevalence of this hantavirus in French Guiana and also the possible undetected mild or moderate cases induced by Maripa virus infection as reported for other New World hantaviruses (13–15). Moreover, it would be informative to determine the infectious potential of the virus in the sequential samples to provide a better understanding of the pathophysiology of this infection. Investigations of the immune response to hantavirus, consequences of different viral loads, and the pathologic characteristics of different hantavirus strains would help identify the determinants of disease outcome.
Dr. Matheus is a research assistant at the Institut Pasteur de la Guyane, Cayenne, French Guiana. Her research interests are the diagnosis and pathophysiology of arboviruses, with special interest in hantavirus circulation in French Guiana.
We thank Sandrine Fernandes-Pellerin and Nathalie Jolly for their helpful expertise on ethics issues relevant to this study. In addition, we acknowledge Thierry Carage for his assistance.
This study was supported in part by the Centre National de Référence des Hantavirus Laboratoire Associé financed by the Institut Pasteur de la Guyane and Santé Publique France (Saint-Maurice, France). This study benefited from the RESERVOIRS program, which is supported by the European Regional Development Fund and Fonds Européen de Developpement Régional, and received assistance from Région Guyane and Direction Régionale pour la Recherche et la Technologie and Investissement d’Avenir grants managed by the Agence Nationale de la Recherche (CEBA ANR-10-LABEX-25-01).
- Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev. 2010;23:412–41.
- Enria DA, Briggiler AM, Pini N, Levis S. Clinical manifestations of New World hantaviruses. Curr Top Microbiol Immunol. 2001;256:117–34.
- Martinez VP, Bellomo CM, Cacace ML, Suarez P, Bogni L, Padula PJ. Hantavirus pulmonary syndrome in Argentina, 1995-2008. Emerg Infect Dis. 2010;16:1853–60.
- MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary syndrome, United States, 1993-2009. Emerg Infect Dis. 2011;17:1195–201.
- Montoya-Ruiz C, Diaz FJ, Rodas JD. Recent evidence of hantavirus circulation in the American tropic. Viruses. 2014;6:1274–93.
- Centers for Disease Control and Prevention. International HPS cases. 2012 [cited 2017 Apr 1]. https://www.cdc.gov/hantavirus/surveillance/international.html
- Matheus S, Djossou F, Moua D, Bourbigot AM, Hommel D, Lacoste V, et al. Hantavirus pulmonary syndrome, French Guiana. Emerg Infect Dis. 2010;16:739–41.
- Matheus S, Lavergne A, de Thoisy B, Dussart P, Lacoste V. Complete genome sequence of a novel hantavirus variant of Rio Mamoré virus, Maripa virus, from French Guiana. J Virol. 2012;86:5399.
- Matheus S, Kallel H, Mayence C, Bremand L, Houcke S, Rousset D, et al. Hantavirus pulmonary syndrome caused by Maripa virus in French Guiana, 2008–2016. Emerg Infect Dis. 2017;23:1722–5.
- Ksiazek TG, Peters CJ, Rollin PE, Zaki S, Nichol S, Spiropoulou C, et al. Identification of a new North American hantavirus that causes acute pulmonary insufficiency. Am J Trop Med Hyg. 1995;52:117–23.
- MacNeil A, Comer JA, Ksiazek TG, Rollin PE. Sin Nombre virus-specific immunoglobulin M and G kinetics in hantavirus pulmonary syndrome and the role played by serologic responses in predicting disease outcome. J Infect Dis. 2010;202:242–6.
- Bostik P, Winter J, Ksiazek TG, Rollin PE, Villinger F, Zaki SR, et al. Sin nombre virus (SNV) Ig isotype antibody response during acute and convalescent phases of hantavirus pulmonary syndrome. Emerg Infect Dis. 2000;6:184–7.
- Bellomo CM, Pires-Marczeski FC, Padula PJ. Viral load of patients with hantavirus pulmonary syndrome in Argentina. J Med Virol. 2015;87:1823–30.
- Terajima M, Hendershot JD III, Kariwa H, Koster FT, Hjelle B, Goade D, et al. High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis. 1999;180:2030–4.
- Xiao R, Yang S, Koster F, Ye C, Stidley C, Hjelle B. Sin Nombre viral RNA load in patients with hantavirus cardiopulmonary syndrome. J Infect Dis. 2006;194:1403–9.
TablesCite This Article
Original Publication Date: 7/31/2018
- Page created: August 15, 2018
- Page last updated: August 15, 2018
- Page last reviewed: August 15, 2018
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)